Do You Have a GLP-1 Drug Lawsuit?

Understanding the Litigation, the Medical Science, and Whether You May Have a Claim

Over the past several years, medications such as Ozempic®, Wegovy®, Mounjaro®, Zepbound®, and Rybelsus® have become household names. Originally developed to help treat Type 2 diabetes and, in some cases, obesity, these medications have helped millions of people lose significant weight and improve their overall health. For many patients, they have been extraordinarily successful.

Their popularity, however, has also given rise to one of the fastest-growing pharmaceutical litigations in the country.

If you’ve seen television commercials or online advertisements asking whether you “qualify” for a GLP-1 lawsuit, you may be wondering whether you have a claim yourself. The answer is not as simple as many advertisements suggest. Most people who take a GLP-1 medication—even those who experience temporary nausea, constipation, or other digestive symptoms—will never have a lawsuit. The current litigation is focused on a much narrower group of patients who allegedly suffered serious injuries beyond the expected side effects of these medications.

As a Michigan product liability attorney, I have followed the development of the GLP-1 litigation closely, including the evolving medical literature, federal court proceedings, and the issues shaping these cases nationwide. My goal is not to tell every reader they have a lawsuit. Instead, it is to explain how this litigation developed, what injuries are currently being alleged, and how to determine whether your circumstances warrant further investigation.

So how do you know whether you may have a case?

Understanding the Litigation

Like many pharmaceutical lawsuits before it, the GLP-1 litigation did not begin because a medication produced common side effects. Rather, lawsuits began after patients alleged they developed serious medical conditions that they claim were not adequately disclosed or warned about.

Today, hundreds of lawsuits involving severe gastrointestinal injuries have been consolidated into a federal multidistrict litigation (MDL) pending in the United States District Court for the Eastern District of Pennsylvania. The litigation is being led by some of the country’s most experienced pharmaceutical product liability firms, together with a Plaintiffs’ Steering Committee appointed by the court to coordinate discovery, expert testimony, and other common issues on behalf of all plaintiffs.

An MDL is often confused with a class action, but the two are very different. Every plaintiff in the GLP-1 MDL has an individual lawsuit and must prove his or her own injuries. The MDL simply allows one court to oversee common discovery, expert testimony, and other pretrial issues before cases are either resolved or returned to their home courts for trial.

More recently, a separate body of litigation has begun involving allegations that certain GLP-1 medications may be associated with non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can result in sudden vision loss. Because the medical evidence differs substantially from the gastrointestinal claims, these cases are developing independently from the existing MDL.

What Are the Lawsuits About?

Although every lawsuit is unique, most current claims allege that manufacturers knew—or should have known—about certain serious risks associated with GLP-1 medications and failed to adequately warn physicians and patients. Those allegations are disputed, and the manufacturers deny liability.

Importantly, these lawsuits are not based upon the idea that every unpleasant side effect should result in compensation. Nausea, vomiting, constipation, and reduced appetite are well-known effects of medications designed to slow gastric emptying. Instead, the litigation generally involves patients who experienced much more significant medical complications, including conditions requiring hospitalization, surgery, or long-term treatment.

As the litigation progresses, both sides will present scientific studies, expert testimony, internal company documents, and medical evidence addressing whether these injuries were caused by the medications and whether additional warnings should have been provided.

Do You Have a Potential GLP-1 Case?

No attorney can responsibly answer that question without reviewing the facts of your individual situation. Nevertheless, most current lawsuits share several common characteristics.

The first is straightforward: the patient used a GLP-1 medication. Most current litigation involves Ozempic®, Wegovy®, Mounjaro®, Zepbound®, or Rybelsus®, although additional medications may become involved as the litigation develops.

Second, the patient was diagnosed with a serious medical condition after taking the medication. The gastrointestinal litigation generally centers on diagnoses such as gastroparesis (sometimes called stomach paralysis), ileus, bowel obstruction, or other severe disorders affecting the normal movement of food through the digestive system. The developing vision litigation generally focuses upon NAION or other qualifying optic nerve injuries.

Third, the injury was significant. While every case is different, many pending lawsuits involve patients who required emergency medical treatment, hospitalization, surgery, repeated medical care, or continue to experience long-term complications related to their injuries.

Finally, there must be medical evidence supporting the claim. Pharmaceutical lawsuits are built upon medical records, physician diagnoses, imaging studies, operative reports, and other objective evidence—not simply a patient’s belief that a medication caused an injury.

A Practical Checklist

If you answer “yes” to many of the following questions, it may be worthwhile to speak with an attorney familiar with the GLP-1 litigation.

Medication

• Did you take Ozempic®, Wegovy®, Mounjaro®, Zepbound®, Rybelsus®, or another GLP-1 medication?

Diagnosis

• Were you diagnosed with gastroparesis (stomach paralysis), ileus, bowel obstruction, severe gastrointestinal dysmotility, NAION, or another serious qualifying injury after beginning the medication?

Treatment

• Did your condition require hospitalization, emergency treatment, surgery, or ongoing specialist care?

Medical Records

• Can your diagnosis and treatment be documented through your medical records?

Timing

• Did your symptoms begin after you started taking the medication?

Should You Speak With an Attorney?

Meeting some—or even all—of the factors above does not automatically mean you have a lawsuit. Likewise, not every potential claim looks exactly the same. Pharmaceutical litigation remains one of the most medically and scientifically complex areas of civil law, and every case depends upon its own medical evidence, the timing of the injury, potential alternative causes, and the current state of the scientific research.

Although these cases are being coordinated nationally, local representation still matters. At JKH Law, we assist Michigan clients in investigating potential GLP-1 claims, obtaining and reviewing medical records, and working with nationally recognized mass tort counsel actively involved in the ongoing litigation when appropriate. Our clients benefit from having a local attorney who understands both the national proceedings and the importance of personalized representation throughout the process.

If you’ve been diagnosed with gastroparesis, bowel obstruction, NAION, or another serious injury after taking a GLP-1 medication, it costs nothing to have your circumstances reviewed. Even if you are uncertain whether your condition qualifies, an early evaluation can help preserve important evidence, answer your questions, and determine whether further investigation is appropriate.